Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

Core Viewpoint - Cocrystal Pharma, Inc. is preparing to present key clinical milestones at two upcoming investment conferences, highlighting its novel antiviral candidates CC-42344 and CDI-988, with expected topline results from clinical trials in 2024 and 2025 [2][3]. Group 1: Upcoming Conferences - Cocrystal Pharma will participate in the Virtual Investor Summit Microcap Forum on August 20, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference starting September 9, 2024 [1][3]. - The management will be available for in-person and virtual one-on-one meetings during the H.C. Wainwright conference, allowing institutional investors and industry professionals to engage directly [3]. Group 2: Clinical Milestones - The company anticipates reporting topline results in 2024 from its Phase 2a challenge study of the influenza A PB2 inhibitor CC-42344, with a final report expected in 2025 [2]. - Topline results from the Phase 1 trial of the oral protease inhibitor CDI-988, targeting norovirus and coronavirus infections, are expected in late 2024 or early 2025 [2]. Group 3: Product Candidates - CC-42344 is a broad-spectrum antiviral candidate designed to treat pandemic and seasonal influenza A, demonstrating favorable safety and pharmacokinetics in earlier studies [4]. - CDI-988 is a novel protease inhibitor aimed at treating norovirus and coronavirus infections, including SARS-CoV-2, currently undergoing a Phase 1 trial for safety and tolerability [5]. Group 4: Company Overview - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing antiviral therapeutics targeting influenza viruses, coronaviruses, noroviruses, and hepatitis C viruses using structure-based drug discovery technologies [6].